Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration

Trial Profile

Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms GALATIR
  • Sponsors Biocad
  • Most Recent Events

    • 30 Mar 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2016 as per ClinicalTrials.gov record.
    • 30 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 12 Jan 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top